

PRESS RELEASE

The start-up company SUBLIMED signs a distribution partnership with Laboratoires Expanscience for its connected transcutaneous electrical nerve stimulation technology

This agreement will enable SUBLIMED to help patients suffering with osteoarthritis-related chronic pain by using this non-drug therapy.

Grenoble, May 15, 2018 - [SUBLIMED](#), a company specializing in the development of non-drug solutions for treating patients with chronic pain, announced today that it has begun a partnership with Laboratoires Expanscience, a French independent dermo-cosmetic and pharmaceutical laboratory that specializes in treating osteoarthritis and skincare.

This agreement states that Expanscience will eventually handle the distribution of its actiTENS® transcutaneous electrical nerve stimulator in France as well as its smartphone application for managing it and collecting patient monitoring data. In February 2018, SUBLIMED obtained the CE mark for its actiTENS® device which is now available, for sale or by prescription in France through its intermediary. .

Expanscience and Sublimed are also partnering in order to carry out a clinical study for increased promotion of actiTENS® to rheumatologists for osteoarthritis by 2020. Particular attention will be paid to patient support, information and training for the effective daily use of this medical device.

"The confidence shown by Laboratoires Expanscience through this contract is a real acknowledgment of our innovative actiTENS technology.. After obtaining the CE mark at the beginning of the year, this is a new major breakthrough for our company," declared Nicolas Karst, CEO of SUBLIMED. "We are delighted to be working with Laboratoires Expanscience on this project after having participated in their start-ups accelerator in 2017. "

"We are pleased to join forces with SUBLIMED's expertise. This partnership is a real step forward in our open innovation approach and represents a promising prospect to enrich our rheumatology portfolio. It demonstrates Expanscience's drive to open up to a wider ecosystem to offer new products and services that help improve the lives of its patients and customers," says Jean-Paul Berthomé, CEO of Laboratoires Expanscience.

Osteoarthritis is a joint disease that affects more than 10 million people in France. It is characterized by the destruction of cartilage which extends to all parts of the joint and which can cause significant pain on a daily basis.

A new approach to relieving chronic pain

SUBLIMED's first product, actiTENS®, is based on a non-drug therapy, transcutaneous electrical nerve stimulation (TENS). actiTENS® is also the first TENS device which discreetly helps the patient in their day-to-day activities and provides them with pain relief in all situations.

actiTENS® comes in the form of a miniature, flexible box that can be placed directly on the body and controlled wirelessly by a smartphone using a dedicated app. This application, developed by SUBLIMED, also enables health professionals to monitor treatment.

About Sublimed

Created in October 2015, SUBLIMED develops innovative solutions for treating chronic pain. A spin-off of CEA, SUBLIMED has an exclusive and global operating license agreement covering a portfolio of patents protecting the actiTENS® device. This transcutaneous electrical nerve stimulation (TENS) device helps to provide chronic pain relief for the patient and discreetly helps them in their day-to-day activities. actiTENS® obtained the CE mark in February 2018.

More information: <http://subli-med.fr/>

About Laboratoires Expanscience

Expanscience, a French independent dermo-cosmetic and pharmaceutical laboratory, generated a turnover of €271.2m in 2017, 61.9% of which was international revenue. Its reputation for reliability, innovation and expertise in the treatment of osteoarthritis and skincare is mainly based on its leading brands, Piascledine 300 and Mustela. Its CSR policy, in force for more than ten years, has been recognized as exemplary by AFAQ 26000 since 2013 and has recently been B CORP certified.

Laboratoires Expanscience in numbers

- Created: 1950
- 102 distributing countries, 16 subsidiaries
- 1,105 employees
- 67 million products manufactured in 2017
- Activities: Dermo-cosmetic, Dermatology, Rheumatology, Cosmetic active ingredients

ingredients

More information: www.expanscience.com

Press contacts

Sublimed

Mahoney Lyle
Céline Gonzalez
cgonzalez@mahoneyle.com
+33 6 75 85 60 42

Nicolas Karst, Sublimed CEO
nicolas.karst@subli-med.com
+33 6 86 65 59 51

Laboratoires Expanscience

Agence ComCorp
Marie-Caroline Saro
mcsaro@comcorp.fr
+33 1 58 18 32 58 | +33 6 88 84 81 74

Sabrina Russo
srusso@comcorp.fr
+33 1 58 18 32 48 | +33 6 82 92 94 45